Study on the Effect of Fecal Microbiota Transplantation on Eradication of Refractory Helicobacter Pylori Infection

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorSichuan Provincial People's Hospital

About this trial

To determine whether regulating the gut microbiota can contribute to the eradication of refractory H. pylori infection.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

1. Ages 18-70

2. Hp infection treatment failed ≥4 times with guidelines-recommended therapies

3. Patients with early gastric cancer, peptic ulcer, gastric MALT lymphoma, atrophic gastritis and other diseases requiring the eradication of Hp.

Disqualifiers

1. Antibiotics and bismuth were taken within 4 weeks before this treatment; Or had taken PPI, H2 receptor antagonist, P-CAB within 2 weeks prior to treatment;

2. Pregnant or lactating women;

3. Those who are allergic to the investigational drugs used in this test or have contraindications;

4. Participated in other drug trials within 3 months before the treatment of this trial;

Trial design

Design model

Single group

Treatments tested in this trial

  • transanal fecal bacteria transplant

    Biological/Vaccine

    Received transanal fecal bacteria transplant

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: washed microbiotaExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Whether Hp is successfully eradicated

The successful eradication of Hp was determined by 13C urea breath test, immunohistochemical staining of Hp and Hp culture.test, immunohistochemical staining of gastric mucosa and Hp culture

Time frame
2years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.